The internationally active, Vienna-based pharmaceutical company AOP Orphan, which specialises in rare diseases, has appointed Suzie McFadzean to join the management team as Chief of Commercial Operations. British-born Suzie McFadzean can draw on over 25 years of experience in the international healthcare sector, bringing above all her management expertise to AOP Orphan. The marketing specialist, who originally trained as a state registered nurse in the UK, moved on to complete an Honours Degree in Combined Sciences, started her career in the pharmaceutical industry at Wyeth in the late 1980s. Whilst progressing through positions of increasing responsibility and geographical reach including Central Eastern Europe and the CIS, she rose to become Assistant Vice President Europe Middle East / Africa & Canada in 2007. In this position, she was responsible for the strategic and commercial management of Wyeth’s vaccine branch. Two years later, she was appointed Vice President of European Vaccines, helping to establish a vaccines division within Pfizer after the takeover of Wyeth. Her next role in Pfizer was Vice President for a large portfolio different franchises, and then went on to be responsible for the leadership of the commercial due diligence team, ultimately resulting in the successful acquisition of Baxter Vaccines by Pfizer.
At AOP Orphan, Suzie McFadzean will first concentrate on implementing a new commercial plan to expand the company’s territorial presence. At the same time, she will prepare the launch of between three and four new products in the business area of Hematology and Gastroenterology.
About AOP Orphan
AOP Orphan was one of the first companies to enter the sector of Rare Diseases in Europe and continues to be a trailblazer in the field of Orphan Diseases to this day. The Orphan Diseases specialist researches, produces and sells innovative solutions, concentrating on three treatment areas: hematology and oncology, cardiology and pulmonology, and neurology and psychiatry. AOP Orphan is active at an international level with an export ratio of 70% and is one of the leading players in the Orphan Drug market.